Is there a role for off‐label high‐efficacy disease‐modifying drugs in progressive multiple sclerosis? A network meta‐analysis
Sign Up to like & getrecommendations! Published in 2022 at "Acta Neurologica Scandinavica"
DOI: 10.1111/ane.13697
Abstract: Ocrelizumab and siponimod are the two on‐label drugs used for progressive forms of multiple sclerosis (PMS). However, many patients with PMS do not have access to these high‐efficacy disease‐modifying drugs (DMDs). Off‐label prescription of other… read more here.
Keywords: network; label high; high efficacy; efficacy ... See more keywords
Pharmacovigilance practice on off-label high-dose of vancomycin in severely ill children
Sign Up to like & getrecommendations! Published in 2025 at "Frontiers in Pharmacology"
DOI: 10.3389/fphar.2025.1680239
Abstract: Purpose To investigate the safety of off-label high-dose vancomycin use in severely ill children and explore strategies to control risks. Methods A case of acute kidney injury caused by off-label high-dose vancomycin (exceeding 40 mg/kg/day)… read more here.
Keywords: label high; severely ill; ill children; high dose ... See more keywords